(Q37729149)

English

Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma

scientific article published on May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

phase I clinical trial

0 references

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Mehmood H Hashmi

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Peter J Van Veldhuizen

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

0 references

publication date

1 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Expert Opinion on Biological Therapy

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

807-817

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin 21: a cytokine/cytokine receptor system that has come of age

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Biology of IL-21 and the IL-21 receptor

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Rising incidence of renal cell cancer in the United States

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Risk factors for childhood melanoma in Queensland, Australia.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Immunotherapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin 21: combination strategies for cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukins. Clinical pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin 2-induced activation of JAK3: possible involvement in signal transduction for c-myc induction and cell proliferation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin-21 signaling: functions in cancer and autoimmunity

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin-21 inhibits dendritic cell activation and maturation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

IL-21 enhances tumor rejection through a NKG2D-dependent mechanism

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Interleukin 21 enhances antibody-mediated tumor rejection

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.480971

21 January 2018

Identifiers

10.1517/14712598.2010.480971

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37729149&oldid=1749491277"